Autoantigen and IL-2 activated CD4+CD25+T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis
Year: 2025
Type: article
Abstract: Experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin basic protein (MBP) is a self-limiting disease model of multiple sclerosis. CD4 + CD25 + Foxp3 + T cells play a role in limiting autoimmune disease but treatment with antigen naïve CD4 + CD25 + cells does not reduce EAE. This study examined if in vitro activation by MBP and rIL-2 induced CD4 + CD25 + Foxp3 + cells that could inhibit EAE. Culture of CD4 + CD8 - CD25 + cells from naïve rats with MBP and rIL-2 induced activated Treg that reduced the severity of clinical EAE and infiltration of CD8 + T cells and macrophage into brain stem. CD4 + CD25 + T cells activated by an irrelevant autoantigen and rIL-2 did not suppress EAE. Resting CD4 + CD25 + T cells activated by autoantigen and rIL-2 have mRNA for Infgr, Il12rb2, Il5 but not Tbet, Gata3, Ilr5ra or Ifng. These changes in mRNA expression are the markers of Ts1 cells. A proportion of CD4 + CD8 - CD25 + cells activated by MBP/rIL-2 were induced to express CD8α, CD8β and CD62L. Depletion of CD4 + CD8α + CD25 + cells removed the capacity of MBP and rIL-2 activated CD4 + CD25 + T cells to suppress EAE. This study demonstrated that in vitro activation of CD4 + CD8 - CD25 + cells by MBP/rIL-2 induced relevant antigen-specific Treg within days, which expressed CD8α, CD8β and CD62L with a Ts1 phenotype and that had greater potency than freshly isolated antigen naive CD4 + CD25 + Treg in suppressing clinical severity of EAE and immune inflammation in CNS. These findings may guide development of antigen-specific Treg for therapy.
Source: Journal of Neuroimmunology
Institutions: UNSW Sydney, Ingham Institute
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,360
Funder: Multiple Sclerosis Australia
Award: G2034844296
OpenAlex ID: W4409253427
